BioSpace News Archive

Portage Biotech Inc. wishes to announce that effective April 15, 2020, the Ontario Securities Commission revoked its Failure-to-File Cease Trade Order issued against the Company on August 2, 2019 and that trading of the Company’s common shares on CSE is expected to resume shortly..

Expanded infectious disease program to address current and potential pandemics builds on existing tuberculosis collaboration Initiation of Phase 2 VERSATILE-002 trial for PDS0101 in advanced/metastatic head and neck cancer delayed due to global COVID-19 pandemic

Food and Drug Administration (FDA) agrees to a trial using the LungFit™ system to treat COVID-19 patients

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2020 financial results on Thursday, May 7 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7 th , at 9:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company’s website a

Pulmatrix, Inc. (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced it has entered into a Collaboration and License Agreement with Sensory Cloud, Inc., a privately held company, led by David Edwards PhD, which specializes in the delivery of aerosolized products for over-the-counter (OTC) healthcare and wellbeing

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 500,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that on Wednesday April 15th, following submission of notification to the U.S. Food and Drug Administration (FDA),

Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company’s Chairman & CEO, Dean Petkanas, was featured in an OTCQB podcast discussing the cannabinoid therapeutics industry and its role in eradicating the current opioid epidemic.

Groundbreaking Technology Provides Long Term Protection From Problematic Bacteria & Viruses

New research from Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving more than 30 million members nationally, found that among commercially insured members with asthma, the number of members who utilized biologics nearly doubled in a 2.5 year span, as did the amount of spending on those medications.